When bulk itraconazole veterinary grade API enters a compounding or licensed manufacturing line, the formulation route is dictated by pH-dependent solubility, particle size distribution, and target species. The compound is a weak triazole base with pKa 3.7, log P 5.66, and aqueous solubility below 1 µg/mL at neutral pH. These properties make it a low-solubility oral candidate in canine and feline formulations, requiring particle size reduction or inclusion complexation before unit-dose production. All bulk API used in the routes below is released against residual solvent limits per VICH GL18 and elemental impurities per ICH Q3D (R2) when the formulation is intended for regulatory filing. The triazole ring is stable under mild acidic and thermal conditions but is sensitive to moisture and alkaline pH, so each downstream process specifies water activity or drying limits. The following applications are separated by manufacturing technology rather than by species, because the critical process parameters differ more between tablet compression, capsule filling, solution compounding, injection sterilisation, and feed premix blending than between cat, dog, bird, and exotic animal target species.

What Limits Direct Compression of Low-Dose Itraconazole Tablets?

In direct compression of dose points at 10 mg or 25 mg, the micronized API’s high electrostatic charge and poor flow produce blend segregation and content uniformity failure. CoAs should specify laser-diffraction particle size by ISO 13320-1:2020, with D90 limits commonly set between 10 µm and 30 µm; the exact D90 ceiling is supplier-specific and must be paired with a bulk density specification during vendor qualification. Lactose monohydrate and microcrystalline cellulose act as fillers, croscarmellose sodium at 2–5 wt% as disintegrant, and magnesium stearate at 0.5 wt% as lubricant. Mixing order must add magnesium stearate in a final short phase not exceeding 5 min at 20–25 rpm in a bin blender, because prolonged lubrication reduces tablet tensile strength by hydrophobic surface film formation. Compression at lower forces of 8–12 kN on a rotary tablet press with 9 mm round tooling yields hardness values of 6–10 kp, friability below 0.8%, and disintegration time below 30 min in 0.1 M HCl at 37±1°C. A pre-compression step at 2–4 kN is applied at turret speeds of 30–60 rpm to reduce lamination and improve die filling. Uniformity of dosage units is evaluated by USP <905>; acceptance value L1=15 for tablets is required. Dissolution testing follows USP <711> using 900 mL of 0.1 M HCl with surfactant levels selected to maintain sink conditions, paddle speed 50 rpm, and Q values established during validation rather than borrowed from human monograph standards. A process conflict arises because micronization increases dissolution rate but reduces powder flow; this is managed by dry granulation when direct compression cannot meet content uniformity, not by increasing lubricant concentration.

Hard gelatin and HPMC capsules containing 25 mg, 50 mg, or 100 mg itraconazole are manufactured on an automatic capsule filling machine equipped with dosator or tamping pin stations. Powder flow is a critical bottleneck because micronized itraconazole exhibits a Carr index above 35 and Hausner ratio above 1.4, indicating poor flowability. To stabilise fill weight at speeds above 20,000 capsules/h, the API is first wet granulated in a high-shear granulator with povidone K30 binder solution, then milled through a 0.8 mm screen and dried to LOD below 1.5%. Fluid-bed drying at inlet air temperature 55–65°C is used to protect the triazole ring from thermal degradation. Capsule fill weights are monitored at intervals of 15 min using USP <905> mass variation methods; acceptance criteria are based on the drug content per capsule rather than fill weight alone. Dissolution of filled capsules is run in 0.1 M HCl with a surfactant such as sodium lauryl sulfate at a concentration sufficient to reach a sink condition of at least three times the saturation solubility, because neutral water media yield artificially low release. HPMC capsules are preferred over hard gelatin for moisture-sensitive formulations because the shell moisture content of hard gelatin at 13–16% can transfer into the granule and accelerate recrystallisation of amorphous itraconazole. Capsules intended for dogs are often administered with food; this increases gastric residence time and improves absorption, while fasting conditions produce more variable Cmax due to pH-dependent dissolution. The finished capsule is tested for water activity below 0.60 aw, microbial quality per USP <61>/<62>, and label claim content by HPLC using a validated method with resolution between itraconazole and related triazole impurities.

pH-Complexation Boundary for Aqueous Oral Solution Vehicles

Because itraconazole free base exhibits pH-dependent solubility that falls below 0.1 µg/mL at pH values above 6.0, solution grade veterinary formulations use hydroxypropyl-β-cyclodextrin (HPβCD) as a complexing agent rather than acidification alone. At pH 3.0–4.0, the molecule is partially protonated and solubility rises, but acid alone does not provide the 10 mg/mL target concentration required for practical dosing. Published human parenteral label data indicate a 1:40 w/w ratio of itraconazole to HPβCD can maintain 10 mg/mL in solution; veterinary oral solution development typically evaluates ratios from 1:10 to 1:40 w/w during phase solubility studies based on the Higuchi-Connors method. Buffers based on citrate or phosphate are selected to hold final pH at 4.0±0.5, because higher pH triggers precipitation as the free base in the non-ionised form, while lower pH increases palatability rejection in cats. Non-aqueous cosolvents such as propylene glycol and sorbitol are added to reduce precipitation when the solution is diluted with saliva or water; however, propylene glycol at high levels is inappropriate in felines due to Heinz-body haemolytic risk, so glycerol and polyethylene glycol grades are used instead. Preservatives must cover the pH range; potassium sorbate and sodium benzoate are less effective above pH 5.0, but the acidic buffered vehicle allows their use at standard compendial concentrations. The solution is filled into amber glass or PET bottles and stored below 25°C; freeze-thaw cycling is avoided because precipitation may be irreversible without high-shear mixing. Dropper accuracy is verified against the labelled dose volume of 0.1 mL increments, and the product is released by HPLC assay, pH, microbial enumeration per USP <61>/<62>, and absence of visible crystallisation after 72 h at 2–8°C.

Terminally sterilised veterinary injection from bulk itraconazole API places the most severe constraints on particle size, bioburden, and cyclodextrin purity. The API is dissolved in water for injection containing HPβCD as a complexing agent; the manufacturing order is critical—itraconazole is added to an acidic aqueous cyclodextrin solution under high-shear mixing, not to water first, to avoid formation of poorly wettable agglomerates. The pH is adjusted to 3.0–4.0 with hydrochloric acid before filtration through a 0.22 µm PVDF or PES membrane; polyvinylidene difluoride is preferred because itraconazole can bind to nylon and certain mixed cellulose ester membranes. Filter integrity is tested by bubble point or forward-flow diffusion before and after filtration. Sterilisation is by autoclaving at 121°C for 15 min after aseptic filling into Type I glass vials, unless the HPβCD concentration and pH stability permit terminal sterilisation, which is the default route when F0 calculations demonstrate a kill effect of at least 15 min at 121°C. Unopened vials are tested for particulate matter by USP <788> or Ph. Eur. 2.9.19, sterility by USP <71>, and bacterial endotoxin by USP <85>; endotoxin limits are set by target species body weight and dose volume. Dilution before infusion must be performed with diluents whose chloride ion concentration and pH do not displace itraconazole from the cyclodextrin cavity; published label data from the human parenteral product indicates compatibility with 0.9% sodium chloride and 5% dextrose, but the final concentration is selected to avoid precipitation over the intended infusion period. Renal function must be considered in exotic animals because high cyclodextrin load may accumulate in proximal tubules; published data for this specific veterinary configuration is limited, so pilot infusion studies with serum biochemistry monitoring are required. Injection-site reactions are a known limitation in birds and small mammals due to the acidic pH and high osmolality of the formulation.

When In-Feed Premix Potency Drops Below 95% After 30-Day Storage

Dry premixes and powders for group-housed exotic mammals or aviary birds are produced by geometric dilution of micronized itraconazole into a carrier such as dextrose monohydrate, lactose monohydrate, or maltodextrin. Geometric dilution begins with a 1:10 API-carrier ratio and proceeds in steps to avoid agglomerates. The primary failure mode is post-mix segregation: the API has a much smaller particle size than the carrier, and vibratory transport on feed carts or augers causes drug-rich fines to migrate downward. To stabilise the blend, the dry powder is converted to granules by wet granulation with povidone or hydroxypropyl methylcellulose binder, dried to LOD below 1.0%, and passed through a 500 µm mesh before blending with feed. Mixing is performed in a V-blender or ribbon blender at 50–60% of nominal capacity; sampling for blend uniformity follows the stratified sampling scheme in ASTM E2810-11e1 with ten points per batch. Potency retention during storage is controlled by water activity and packaging: aluminium foil-lined multiwall bags are sealed at 20–25°C and <40% RH, because moisture exposure above 60% RH promotes recrystallisation and reduces dissolution rate. A 30-day point-of-use stability study with sampling at 0, 15, and 30 days is often required when the premix is distributed in medicated feed. Analytical release includes assay by HPLC, loss on drying, bulk density, tapped density, and sieve analysis by Ph. Eur. 2.9.38 or USP <786>. The use of itraconazole premix in food-producing species is not authorised in several jurisdictions; therefore this formulation route is directed to non-food companion, aviary, zoo, and laboratory animal settings where medicated feed can be weighed precisely.

For patients too small to accept tablets or capsules, granules for oral syringe administration in reptiles and large birds are dry-milled, free-flowing aggregates with particle sizes between 250 µm and 1000 µm to enable suspension in water or methylcellulose gel at the point of administration. The granules are prepared by slugging or dry granulation of a preblend containing lactose, microcrystalline cellulose, and crospovidone; dry granulation is preferred over wet granulation when a low-moisture environment is critical for heat-sensitive species. If wet granulation is unavoidable, the binder is hydroxypropyl cellulose at 5 wt%, and the granulation is dried at 45–55°C until LOD is below 1.5%. The finished granules are tested for Hausner ratio below 1.25 and Carr index below 25 to ensure reproducible volumetric dosing with a syringe adapter. Reconstitution with water forms a suspension that must be used within 24 h and shaken immediately before each dose; settling velocity is controlled by increasing the viscosity with 0.3–0.5% xanthan gum or methylcellulose. Pass-through of the granules through a 1.2 mm oral syringe tip is verified to avoid clogging in small reptile patients. The dissolution test for granules is conducted in 0.1 M HCl at 37°C with 50 rpm paddle and sink conditions ensured by surfactant addition; acceptance is based on Q at 45 min established during formulation validation.

Where tablets or capsules cannot be administered to fractious cats or small exotic patients, powders for medicated soft chews are produced by dry adsorption of itraconazole onto silicon dioxide or porous maltodextrin before mixing with lipid binders and palatants. The adsorption step reduces caking during storage and improves the distribution of the hydrophobic API in a high-fat matrix. Lipid binder melt temperature is held at 35–45°C during mixing; excursions above 50°C are avoided unless the API is pre-complexed with cyclodextrin because amorphous and crystalline forms of itraconazole have different solubility and bioavailability signatures. The chew matrix is extruded through a cold-forming extruder with barrel temperature zones not exceeding 45°C, cut into unit doses, and cooled rapidly to room temperature to avoid fat bloom and non-uniform API distribution. Each chew is tested for water activity below 0.65 aw, hardness or texture by texture analyser, and yeast and mold counts per USP <61>/<62>. Dissolution testing of lipid-based chews requires media containing surfactant because the triglyceride phase can retain drug and delay release; a paddle speed of 75 rpm may be used when the dosage form does not disintegrate readily at 50 rpm. The main process limitation is that high-fat soft chews can reduce the rate of itraconazole release in fasted cats; gastric emptying and lipase activity are therefore part of formulation batch review rather than assumed from immediate-release solid oral data.